E-Cigarette Use and Risk of Cardiovascular Disease: A Longitudinal Analysis of the PATH Study (2013–2019)

Berlowitz, Jonathan B.; Xie, Wubin; Harlow, Alyssa F.; Hamburg, Naomi M.; Blaha, Michael; Bhatnagar, Aruni; Benjamin, Emelia J.; Stokes, Andrew

doi:10.1161/circulationaha.121.057369

Cited by 53 publications

(27 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Il rischio cardiovascolare (CV) nell'uso duale di e-cig e sigarette tradizionali è simile a quello dei fumatori esclusivi di tabacco [7][8][9][10]. La nicotina e il particolato (PM) delle e-cig determinano un aumento della frequenza cardiaca e della pressione sistolica e diastolica; aumento delle specie reattive dell'ossigeno; diminuzione dell'attività antiossidante; aumento della disfunzione endoteliale e dell'attivazione piastrinica.…”

Section: Rischio Cardiovascolare Delle E-cigunclassified

“…La nicotina e il particolato (PM) delle e-cig determinano un aumento della frequenza cardiaca e della pressione sistolica e diastolica; aumento delle specie reattive dell'ossigeno; diminuzione dell'attività antiossidante; aumento della disfunzione endoteliale e dell'attivazione piastrinica. Inoltre, gli studi sull'inquinamento atmosferico e sul fumo di tabacco hanno mostrato un rischio maggiore di mortalità per infarto miocardico acuto [7][8][9][10]. Pertanto, le e-cig non dovrebbero essere considerate un prodotto sicuro per il rischio cardiovascolare.…”

Section: Rischio Cardiovascolare Delle E-cigunclassified

“…The cardiovascular (CV) risk in dual use of e-cigs and traditional cigarettes is similar to that in exclusive tobacco smokers [7][8][9][10]. Nicotine & Particulate Matter (PM) from e-cigs determine increases of heart rate, systolic & diastolic blood pressure; reactive oxygen species; decrease of antioxidant activity; increase of endothelial dysfunction and platelet activation.…”

Section: Cardiovascular Risk Of E-cigsmentioning

confidence: 99%

“…Nicotine & Particulate Matter (PM) from e-cigs determine increases of heart rate, systolic & diastolic blood pressure; reactive oxygen species; decrease of antioxidant activity; increase of endothelial dysfunction and platelet activation. Moreover, PM from ambient air pollution and tobacco smoking studies determine higher risk of CV mortality (acute myocardial infarction) [7][8][9][10]. Thus, e-cigs should not be regarded as a CV safe product.…”

Section: Cardiovascular Risk Of E-cigsmentioning

confidence: 99%

See 3 more Smart Citations

Atti XXIV Convegno Nazionale Tabagismo e SSN - Update on electronic cigarettes and heated tobacco products

Gorini

2022

Tabaccologia

View full text Add to dashboard Cite

Section: Rischio Cardiovascolare Delle E-cigunclassified

Section: Cardiovascular Risk Of E-cigsmentioning

confidence: 99%

Section: Cardiovascular Risk Of E-cigsmentioning

confidence: 99%

See 2 more Smart Citations

Atti XXIV Convegno Nazionale Tabagismo e SSN - Update on electronic cigarettes and heated tobacco products

Gorini

2022

Tabaccologia

View full text Add to dashboard Cite

“…Epidemiological studies of novel tobacco products currently face challenges including the long time-course of cardiovascular disease pathogenesis and confounding caused by previous and current use of other tobacco products in study subjects ( 25 ). One analysis of Waves 1 through 5 (2013-2019) of the Population Assessment of Tobacco and Health (PATH) Study found reduced risk of HF, myocardial infarction, and stroke in exclusive electronic cigarette users vs. combustible tobacco users ( 26 ); a second analysis of this cohort found no differences in cardiovascular disease events between combustible tobacco users, those who transitioned to electronic cigarette use or dual-use, and those that quit tobacco products ( 27 ). Authors of both studies, however, indicate significant limitations surrounding short follow-up duration in relation to the disease endpoints ( 26 , 27 ).…”

Section: Introductionmentioning

confidence: 98%

Nicotine and novel tobacco products drive adverse cardiac remodeling and dysfunction in preclinical studies

Fried

Oakes²,

Whitehead³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThe heart undergoes structural and functional changes in response to injury and hemodynamic stress known as cardiac remodeling. Cardiac remodeling often decompensates causing dysfunction and heart failure (HF). Cardiac remodeling and dysfunction are significantly associated with cigarette smoking. Although cigarette smoking has declined, the roles of nicotine and novel tobacco products (including electronic cigarettes and heat-not-burn tobacco) in cardiac remodeling are unclear. In this perspective, we present evidence demonstrating maladaptive cardiac remodeling in nicotine-exposed mice undergoing hemodynamic stress with angiotensin (Ang)-II infusion and review preclinical literature linking nicotine and novel tobacco products with cardiac remodeling and dysfunction.MethodsAdult, male C57BL/6J mice were exposed to room air or chronic, inhaled nicotine for 8 weeks. A subset of mice was infused with Ang-II via subcutaneous osmotic mini-pumps during the final 4 weeks of exposure. Left ventricular structure and function were assessed with echocardiography.ResultsChronic, inhaled nicotine abrogated Ang-II-induced thickening of the left ventricular posterior wall, leading to reduced relative wall thickness. Ang-II infusion was associated with increased left ventricular mass index in both air- and nicotine-exposed mice.ConclusionsThese changes suggest a phenotypic shift from concentric hypertrophy to eccentric hypertrophy in nicotine-exposed, hemodynamically-stressed mice which could drive HF pathogenesis. These findings join a growing body of animal studies demonstrating cardiac remodeling and dysfunction following nicotine and electronic cigarette exposure. Further exploration is necessary; however, clinicians and researchers should not overlook these emerging products as potential risk factors in the pathogenesis of cardiac remodeling and associated diseases including HF.

show abstract

E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions

2023

View full text Add to dashboard Cite

show abstract

E-Cigarette Use and Risk of Cardiovascular Disease: A Longitudinal Analysis of the PATH Study (2013–2019)

Cited by 53 publications

References 5 publications

Atti XXIV Convegno Nazionale Tabagismo e SSN - Update on electronic cigarettes and heated tobacco products

Atti XXIV Convegno Nazionale Tabagismo e SSN - Update on electronic cigarettes and heated tobacco products

Nicotine and novel tobacco products drive adverse cardiac remodeling and dysfunction in preclinical studies

E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions

Contact Info

Product

Resources

About